ReviewThorax2013
Pneumonia in low and middle income countries: progress and challenges.
Review in Thorax, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diabetes comorbidities in low- and middle-income countries: An umbrella review.Journal of global health · 2021Pooled it
- Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months.The Cochrane database of systematic reviews · 2017Pooled it
- Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review.Human vaccines & immunotherapeutics · 2016Pooled it
- Global, regional, and national estimates of pneumonia burden in HIV-infected children in 2010: a meta-analysis and modelling study.The Lancet. Infectious diseases · 2014Pooled it
- Etiology and efficacy of anti-microbial treatment for community-acquired pneumonia in adults requiring hospital admission in Ukraine.Acta bio-medica : Atenei Parmensis · 2022Trial
- Evaluation and Comparison of Antibiotic Prescribing Practices and Treatment Outcomes in Children with Pneumonia Admitted to Public and Private Hospitals in Pakistan: A Retrospective Study.Journal of epidemiology and global health · 2026Observational
- Diagnostic performance of lung ultrasound and procalcitonin in differentiating early neonatal pneumonia from transient tachypnea of the newborn.BMC pediatrics · 2026Observational
- Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single-Arm Meta-Analysis of Prevalence Data.Health science reports · 2026Review
- Adapting global guidelines to local contexts: optimising community-acquired pneumonia (CAP) specific prescribing in Pakistan to counter antimicrobial resistance.BMJ open respiratory research · 2025Article
- D-PRISM: a global survey-based study to assess diagnostic and treatment approaches in pneumonia managed in intensive care.Critical care (London, England) · 2024Article
- Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024).Lung India : official organ of Indian Chest Society · 2024Article
- Clinical predictors of hypoxic pneumonia in children from the Eastern Highlands Province, Papua New Guinea: secondary analysis of two prospective observational studies.The Lancet regional health. Western Pacific · 2024Article
- Treatment outcome of pneumonia and its associated factors among pediatric patients admitted to Hiwot Fana Comprehensive Specialized University Hospital, Eastern Ethiopia.Frontiers in pediatrics · 2024Article
- Human genetic determinants of COVID-19 in Brazil: challenges and future plans.Genetics and molecular biology · 2024Article
- Nanofluidic qPCR unable to detect and serotype Streptococcus pneumoniae in urine samples of hospitalized South African patients with community-acquired pneumonia.Scientific reports · 2023Article
- Magnetic Nanoclusters Increase the Sensitivity of Lateral Flow Immunoassays for Protein Detection: Application to Pneumolysin as a Biomarker forNanomaterials (Basel, Switzerland) · 2022Article
- Using tea nanoclusters as β-lactamase inhibitors to cure multidrug-resistant bacterial pneumonia: A promising therapeutic strategy by Chinese materioherbology.Fundamental research · 2022Article
- The HEV Ventilator: at the interface between particle physics and biomedical engineering.Royal Society open science · 2022Article
- Article
- Aetiology and prognosis of community-acquired pneumonia at the Adult University Teaching Hospital in Zambia.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pneumonia remains the leading cause of childhood mortality and the most common reason for adult hospitalisation in low and middle income countries, despite advances in preventative and management strategies. In the last decade, pneumonia mortality in children has fallen to approximately 1.3 million cases in 2011, with most deaths occurring in low income countries. Important recent advances include more widespread implementation of protein-polysaccharide conjugate vaccines against Haemophilus influenzae type B and Streptococcus pneumoniae, implementation of case-management algorithms and better prevention and treatment of HIV. Determining the aetiology of pneumonia is challenging in the absence of reliable diagnostic tests. High uptake of new bacterial conjugate vaccines may impact on pneumonia burden, aetiology and empiric therapy but implementation in immunisation programmes in many low and middle income countries remains an obstacle. Widespread implementation of currently effective preventative and management strategies for pneumonia remains challenging in many low and middle income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.